세계의 크론병 치료 시장 보고서(2025년)
Crohn´s Disease (CD) Treatment Global Market Report 2025
상품코드 : 1824631
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,648,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,609,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,571,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

크론병 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.1%를 나타내 150억 1,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 병용요법 수요 증가, 생물학적 제제의 채용 확대, 크론병 치료에 관한 연구개발에 대한 투자 등에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향에는 생물학적 제제 개발, 혁신적인 제품, 고급 진단 도구, 바이오시밀러 채택 등이 포함됩니다.

향후 5년간의 성장률 5.1%라는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 스위스와 덴마크에서 공급되는 단일클론항체 치료제의 가격을 끌어올려 염증성 장질환(IBD) 관리를 위한 자기부담액을 악화시켜 치료의 어드히어런스를 저하시킴으로써 미국 환자에게 부담을 강하게 할 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

염증성 장 질환의 유병률 증가는 앞으로 수년간 크론병 치료 시장 성장을 가속할 것으로 예측됩니다. 염증성 장 질환(IBD)은 주로 위장관(GI)관에 영향을 미치는 만성 염증성 질환군을 포함합니다. 크론병 치료는 증상을 완화하고, 염증을 억제하고, 관해를 촉진하며, 만성 염증성 장 질환을 앓고 있는 사람의 전반적인 삶의 질을 개선하는 데 도움이 됩니다. 예를 들어 미국에 본부를 두는 의학도서관인 미국 국립의학도서관은 2023년 9월 캐나다에서 IBD의 이환율을 10만명당 30례로 추정하며 매년 약 0.58%씩 꾸준히 증가할 것으로 예측했습니다. 2023년 기준 캐나다에서 IBD의 유병률은 10만명당 약 825명에 달했으며 2035년에는 인구의 1.1%까지 증가할 것으로 예상됩니다. 따라서 염증성 장 질환의 유병률 증가는 크론병 치료에 대한 수요를 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Crohn's disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn's disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

The primary categories of drugs used in the treatment of Crohn's disease are antibiotics, aminosalicylates, corticosteroids, immunomodulators, and other types of medications. Antibiotics are drugs that combat bacterial infections by either killing the bacteria or inhibiting their growth and reproduction. These drugs can be administered orally or via injection, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The Crohn's disease treatment market research report is one of a series of new reports from The Business Research Company that provides Crohn's disease treatment market statistics, including Crohn's disease treatment industry global market size, regional shares, competitors with a Crohn's disease treatment market share, detailed Crohn's disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the Crohn's disease treatment industry. This Crohn's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The crohn's disease (cd) treatment market size has grown steadily in recent years. It will grow from $11.76 billion in 2024 to $12.32 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to rising prevalence of crohn's disease, growing awareness of the disease, government initiatives, changing lifestyle.

The crohn's disease (cd) treatment market size is expected to see strong growth in the next few years. It will grow to $15.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to growing demand for combination therapies, increasing adoption of biologics, investments in research and development on crohn's disease (cd) treatments. Major trends in the forecast period include development biologic drugs, innovative products, advanced diagnostic tools, biosimilars adoption.

The forecast of 5.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of monoclonal antibody therapies sourced from Switzerland and Denmark, exacerbating out-of-pocket expenses for Inflammatory Bowel Disease(IBD) management and reducing treatment adherence. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of inflammatory bowel diseases is expected to drive the growth of the Crohn's disease (CD) treatment market in the coming years. Inflammatory bowel disease (IBD) encompasses a group of chronic inflammatory conditions that primarily affect the gastrointestinal (GI) tract. Treatments for Crohn's disease (CD) help alleviate symptoms, reduce inflammation, encourage remission, and improve the overall quality of life for individuals affected by chronic inflammatory bowel disease. For example, in September 2023, the United States National Library of Medicine, a medical library based in the US, estimated that the incidence of IBD in Canada was 30 cases per 100,000 person-years in 2023, with projections showing a steady annual increase of about 0.58%. As of 2023, the prevalence of IBD in Canada reached approximately 825 per 100,000, with predictions indicating it could rise to 1.1% of the population by 2035. Thus, the growing prevalence of inflammatory bowel diseases is driving the demand for Crohn's disease (CD) treatments.

Anticipated growth in the Crohn's disease treatment market can be attributed to the increasing number of clinical trials. Clinical trials are crucial for assessing the safety and effectiveness of new therapies, potentially leading to regulatory approvals and the introduction of novel treatment options for Crohn's disease (CD) patients. The demand for more efficient CD treatments encourages clinical trials, driven by the desire of patients and healthcare providers for improved outcomes with reduced side effects, thereby stimulating research and development endeavors. For example, the University of California reported 17 ongoing clinical trials focused on vedolizumab, oral ozanimod, and the long-term efficacy of mirikizumab for pediatric CD and ulcerative colitis patients, highlighting the proliferation of clinical trials in the fie

Leading companies in the Crohn's disease (CD) treatment market are focused on the introduction of innovative technologies like IBDSENSE to maintain their market position. An example of this is the development of IBDSENSE by The IRR Chemistry Hub, an interdisciplinary hub based in Scotland. IBDSENSE is designed to enhance the diagnosis and monitoring of inflammatory bowel diseases, including Crohn's disease, through non-invasive methods. The technology utilizes fluorescence-based techniques to measure the enzyme activity of Granzyme B (GzmB) in patient biosamples, aiming to enhance the patient experience and treatment options.

In June 2023, Merck & Co. Inc., a pharmaceutical company based in the United States, completed its acquisition of Prometheus Biosciences Inc. for a total of $10.8 billion. This strategic move by Merck & Co. is intended to broaden its range of products related to the treatment of immunological and inflammatory conditions. Prometheus Biosciences, a biotechnology company based in the United States, specializes in the development of drugs for inflammatory diseases, particularly in the areas of Crohn's disease and inflammatory bowel disease treatments.

Major companies operating in the crohn's disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.

North America was the largest region in the Crohn's disease (CD) treatment market in 2024. The regions covered in Crohn's disease (CD) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Crohn's disease (CD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Crohn's disease (CD) treatment market consists of sales of Janus kinase inhibitors and anti-inflammatory drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Crohn's Disease (CD) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on crohn's disease (cd) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for crohn's disease (cd) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The crohn's disease (cd) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Crohn's Disease (CD) Treatment Market Characteristics

3. Crohn's Disease (CD) Treatment Market Trends And Strategies

4. Crohn's Disease (CD) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Crohn's Disease (CD) Treatment Growth Analysis And Strategic Analysis Framework

6. Crohn's Disease (CD) Treatment Market Segmentation

7. Crohn's Disease (CD) Treatment Market Regional And Country Analysis

8. Asia-Pacific Crohn's Disease (CD) Treatment Market

9. China Crohn's Disease (CD) Treatment Market

10. India Crohn's Disease (CD) Treatment Market

11. Japan Crohn's Disease (CD) Treatment Market

12. Australia Crohn's Disease (CD) Treatment Market

13. Indonesia Crohn's Disease (CD) Treatment Market

14. South Korea Crohn's Disease (CD) Treatment Market

15. Western Europe Crohn's Disease (CD) Treatment Market

16. UK Crohn's Disease (CD) Treatment Market

17. Germany Crohn's Disease (CD) Treatment Market

18. France Crohn's Disease (CD) Treatment Market

19. Italy Crohn's Disease (CD) Treatment Market

20. Spain Crohn's Disease (CD) Treatment Market

21. Eastern Europe Crohn's Disease (CD) Treatment Market

22. Russia Crohn's Disease (CD) Treatment Market

23. North America Crohn's Disease (CD) Treatment Market

24. USA Crohn's Disease (CD) Treatment Market

25. Canada Crohn's Disease (CD) Treatment Market

26. South America Crohn's Disease (CD) Treatment Market

27. Brazil Crohn's Disease (CD) Treatment Market

28. Middle East Crohn's Disease (CD) Treatment Market

29. Africa Crohn's Disease (CD) Treatment Market

30. Crohn's Disease (CD) Treatment Market Competitive Landscape And Company Profiles

31. Crohn's Disease (CD) Treatment Market Other Major And Innovative Companies

32. Global Crohn's Disease (CD) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Crohn's Disease (CD) Treatment Market

34. Recent Developments In The Crohn's Disease (CD) Treatment Market

35. Crohn's Disease (CD) Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기